In vitro and in vivo antitumor activity of liposomal Fenretinide targeted to human neuroblastoma

International Journal of Cancer

Volumn 104, Issue 5, 2003, Pages 559-567

  Raffaghello, Lizzia ^a   Pagnan, Gabriella ^a   Pastorino, Fabio ^a   Cosimo, Emilio ^a   Brignole, Chiara ^a   Marimpietri, Danilo ^a   Montaldo, Paolo G ^a   Gambini, Claudia ^a   Allen, Theresa M ^b   Bogenmann, Emil ^c   Ponzoni, Mirco ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Disialoganglioside 2; Fenretinide; Immunoliposomes; Neuroectodermal tumors; Targeted drug delivery

Indexed keywords

DISIALOGANGLIOSIDE GD2; FENRETINIDE; GANGLIOSIDE GD2; IMMUNOLIPOSOME; LIPOSOME; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING COMPETITION; CANCER CELL CULTURE; CELL GROWTH; CHILDHOOD CANCER; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA CELL; METASTASIS; NEUROBLASTOMA; NEUROECTODERM TUMOR; PRIORITY JOURNAL; PROGNOSIS; SOLID TUMOR;

ANIMALS; APOPTOSIS; CELL DIVISION; DISEASE MODELS, ANIMAL; FENRETINIDE; HUMANS; LIPOSOMES; MICE; MICE, NUDE; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; SURVIVAL ANALYSIS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037401058     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10991     Document Type: Article

References (48)

1. Seeger RC, Reynolds CP. Neoplasms in children: neuroblastoma. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL. Weichselbaum RR, eds. Cancer medicine. Philadelphia: Lea & Febiger, 1993. 2172-84.
2. Maris JM, Matthay KK. Molecular biology of neuroblastoma. J Clin Oncol 1999;17:2264-79.
3. Niethammer D, Handgretinger R. Clinical strategies for the treatment of neuroblastoma. Eur J Cancer 1995;31A:568-71.
4. Burek MJ, Oppenheim RW. Programmed cell death in the developing nervous system. Brain Pathol 1996;6:427-46.
5. Marx J. Cell death studies yield cancer clues. Science 1993;279:760-1.
6. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74:957-67.
7. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy (editorial). J Natl Cancer Inst 1995;87:1655-7.
8. Pollard M, Luckert PH, Sporn MB. Prevention of primary prostate cancer in Lobund-Wistar rats by N-(4-hydroxyphenyl)retinamide. Cancer Res 1991;51:3610-1.
9. Lo Piccolo MS, Formelli F, Lulsch R, Ponzoni M, Montaldo PG, De Bernardi B, Bellani FF, Garaventa A. Phase I study of Fenretinide in neuroblastoma. Am Assoc Cancer Res 2000;PC22:61.
10. Pagnan G, Caridi G, Montaldo PG, Bado M, Chiesa V, Allen MT, Ponzoni M. Apoptosis of human neuroblastoma cells induced by liposome-encapsulated Fenretinide. J Liposome Res 1998;8:401-23.
11. Allen TM. Long-circulating (sterically stabilized) liposomes for targeted drug delivery. TiPS 1994;15:215-20.
12. Gabizon AA, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994;54:987-92.
13. Allen TM, Brandeis E, Hansen CB, Kao GY, Zalipsky S. A new strategy for attachment of antibodies to sterically stabilized liposomes resulting in efficient targeting to cancer cells. Biochim Biophys Acta 1995;1237:99-108.
14. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D. Pharmacokinetics and therapeutics of sterically stabilized liposomes in mice bearing C-26 colon carcinoma. Cancer Res 1992;52:5135-43.
15. Mujoo K, Cheresh DA, Yang HM, Reisfeld RA. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. Cancer Res 1986;47:1098-104.
16. Schulz G, Cheresh DA, Vark NM, Yu A. Staffileno LK, Reisfeld RA. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res 1984;44:5914-20.
17. Wargalla UC, Reisfeld RA. Rate of internalization of an immunotoxin correlates with cytotoxic activity against human tumor cells. Proc Natl Acad Sci USA 1989;86:5146-50.
18. Frost JD, Hank JA, Reaman GH, Frierdich S, Seeger RC, Gan J, Anderson PM, Ettinger LJ, Cairo MS, Blazar BR, Krailo MD, Matthay KK, Reisfeld RA, Sondel PM. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group. Cancer 1997;80:317-33.
19. Pagnan G, Montaldo PG, Pastorino F, Raffaghello L, Kirchmeier M, Allen TM, Ponzoni M. GD2-mediated melanoma cell targeting and cytotoxicity of liposome-entrapped Fenretinide. Int J Cancer 1999;81:268-74.
20. Allen TM, Hansen C, Martin F, Redemann C, Yau-Young A. Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. Biochim. Biophys. Acta 1991;1066:29-36.
21. Honsik CJ, Jung G, Reisfeld RA. LAK cells targeted by monoclonal antibody to the disialoganglioside GD2 and GD3 specifically lyse human tumor cells of neuroectodermal origin. Proc Natl Acad Sci USA 1986;83:7983-7.
22. Huwlyer J, Dafang W, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996;93:14164-9.
23. Lopes De Menezes DE, Pilarski LM, Allen TM. In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma. Cancer Res 1998;8:3320-30.
24. Hansen CB, Kao GY, Moase EH, Zalipsky S, Allen TM. Attachment of antibodies to sterically stabilized liposomes: evaluation, comparison and optimization of coupling procedure. Biochim Biophys Acta 1995;1239:133-44.
25. Pagnan G, Stuart DD, Pastorino F, Raffaghello L, Montaldo PG, Allen MT, Calabretta B, Ponzoni M. Delivery of c-myb antisense oligodeoxynucleotides to human neuroblastoma cells via disialoganglioside GD2-targeted immunoliposomes: antitumor effect. J Natl Cancer Inst 2000;92:253-61.
26. Moon RC, Thompson HJ, Becci PJ, Grubbs CJ, Gander RJ, Newton DL, Smith JM, Philips SL, Henderson WR, Mullen LT, Brown CC. Sporn MB. N-(4-hydroxyphenyl)retinamide, a new retinoid for prevention of breast cancer in the rat. Cancer Res 1979;39:1339-46.
27. Ponzoni M, Bocca P, Chiesa V, Decensi A, Pistoia V, Raffaghello L, Rozzo C, Montaldo PG. Differential effects of N-(4-hydroxyphenyl-)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation. Cancer Res 1995;55:853-61.
28. Montaldo PG, Chiesa V, Bado M, Raffaghello L, Rozzo C, Ponzoni M. Induction of differentiation and apoptosis by interferon-γ in human neuroblastoma cells in vitro as a dual and alternative early biological response. Cell Death Differ 1997;4:150-8.
29. Matzinger P. The JAM test: a simple assay for DNA fragmentation and cell death. J Immunol Methods 1981;145:185-8.
30. Matsushima H, Bogenmann E. Bi-modal differentiation pattern in a new human neuroblastoma cell line in vitro. Int J Cancer 1992;51:250-8.
31. Bogenmann E. A metastatic neuroblastoma model in SCID mice. Int J Cancer 1996;67:381-6.
32. Montaldo PG, Pagnan G, Pastorino F, Chiesa V, Raffaghello L, Kichmeier M, Allen TM, Ponzoni M. N-(4-hydroxyphenyl)retinamide is cytotoxic to melanoma cell in vitro through induction of programmed cell death. Int J Cancer 1999;81:262-7.
33. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death. In situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:365-9.
34. Olshan AF, Bunin GR. Epidemiology of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, eds. Neuroblastoma. New York: Elsevier, 2000. 33-7.
35. Hitoshi I, Castle VP. Apoptosis in neuroblastoma and pathways involving Bcl-2 and caspases. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, eds. Neuroblastoma. New York: Elsevier, 2000. 9-16.
36. Kalemkerian GP, Slusher R, Ramalingam S, Gadgeel S, Mabry M. Growth inhibition and induction of apoptosis by fenretinide in small-cell lung cancer cell lines. J Natl Cancer Inst 1995;87:1674-80.
37. Formelli F, Clerici M, Campa T, Di Mauro MG, Agni A, Mascotti G, Moglia D, De Palo G, Costa A. Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 1993;11:2036-42.
38. Ahmad I, Longenecker M, Samuel J, Allen TM. Antibody-targeted delivery of doxorubicin entrapped in sterically stabilized liposomes can eradicate lung cancer in mice. Cancer Res 1993;53:1484-8.
39. Allen TM, Ahmad I, Lopes De Menezes DE, Moase EH. Immunoliposomes-mediated targeting of anti-cancer drugs in vivo. Biochem Soc Trans 1995;23:1073-9.
40. Weinstein JN, Van Osdol W. Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier." Cancer Res 1992;52:2747-51.
41. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res 1994;54:3352-6.
42. Moss TY, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991;324:219-6.
43. Al-Mehdi AB, Tozawa K, Fisher AB, Shienag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 2000;6:100-2.
44. Luzzi KJ, MacDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153:865-73.
45. Ozkaynak MF, Sondel PM, Krailo MD, Gan J, Javorsky B, Reisfeld RA, Matthay KK, Reaman GH, Seeger RC. Phase I study of chimeric human/murine anti-Ganglioside GD2 monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a children's cancer group study. J Clin Oncol 2000;18:4077-85.
46. Kushner BH, Kramer K, Cheung NKV. Phase II trial of the anti-GD2 monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol 2001;19:4189-94.
47. Raffaghello L, Marimpietri D, Pagnan G, Pastorino F, Cosimo E, Brignole C, Ponzoni M, Montaldo PG. Anti-GD2 monoclonal antibody immunotherapy: a promising strategy in the prevention of neuroblastoma relapse. Cancer Letters 2003; in press.
48. Cheung N-KV, Yu AL. Immunotherapy of neuroblastoma. In: Brodeur GM, Sawada T, Tsuchida Y, Voute PA, eds. Neuroblastoma. New York: Elsevier, 2000. 541.